Tetanus - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 100
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TF29B642DAEEN
Leaflet:

Download PDF Leaflet

Tetanus - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Tetanus - Pipeline Review, H2 2016’, provides an overview of the Tetanus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Tetanus
  • The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects
  • The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tetanus
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tetanus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Tetanus Overview
Therapeutics Development
Pipeline Products for Tetanus - Overview
Pipeline Products for Tetanus - Comparative Analysis
Tetanus - Therapeutics under Development by Companies
Tetanus - Therapeutics under Investigation by Universities/Institutes
Tetanus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Tetanus - Products under Development by Companies
Tetanus - Products under Investigation by Universities/Institutes
Tetanus - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Bharat Biotech International Limited
BioClonetics Immunotherapeutics, Inc.
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Green Cross Corporation
Indian Immunologicals Limited
Kaketsuken K.K.
LG Life Science LTD.
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
Tetanus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eupenta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-1107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Tetanus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Tetanus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target Tetanus Toxin for Tetanus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetanus - Dormant Projects
Tetanus - Discontinued Products
Tetanus - Product Development Milestones
Featured News & Press Releases
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency
Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 100

LIST OF TABLES

Number of Products under Development for Tetanus, H2 2016
Number of Products under Development for Tetanus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
Tetanus - Pipeline by Bharat Biotech International Limited, H2 2016
Tetanus - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
Tetanus - Pipeline by Biological E. Limited, H2 2016
Tetanus - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016
Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2016
Tetanus - Pipeline by Green Cross Corporation, H2 2016
Tetanus - Pipeline by Indian Immunologicals Limited, H2 2016
Tetanus - Pipeline by Kaketsuken K.K., H2 2016
Tetanus - Pipeline by LG Life Science LTD., H2 2016
Tetanus - Pipeline by Panacea Biotec Limited, H2 2016
Tetanus - Pipeline by Prometheon Pharma, LLC, H2 2016
Tetanus - Pipeline by Sanofi Pasteur SA, H2 2016
Tetanus - Pipeline by Serum Institute of India Limited, H2 2016
Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2016
Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Tetanus - Dormant Projects, H2 2016
Tetanus - Dormant Projects (Contd..1), H2 2016
Tetanus - Discontinued Products, H2 2016 88

LIST OF FIGURES

Number of Products under Development for Tetanus, H2 2016
Number of Products under Development for Tetanus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Tetanus - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 92 pages
Sanofi Pasteur SA - Product Pipeline Review - 2016 US$ 1,275.00 Mar, 2016 · 59 pages
Biological E. Limited - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 29 pages

Ask Your Question

Tetanus - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: